Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The adipocyte enhancer binding protein 1 is a transcriptional repressor with carboxypeptidase (CP) activity. Additionally we are shipping AEBP1 Antibodies (47) and AEBP1 Proteins (3) and many more products for this protein.
Showing 4 out of 11 products:
ACLP stimulates the fibroblast-to-myofibroblast transition by promoting SMA (show SMN1 ELISA Kits) expression via TGFbeta (show TGFB1 ELISA Kits) signaling and promoting collagen expression through a TGFbeta (show TGFB1 ELISA Kits) receptor-independent pathway.
There is no statistically significant differences in the frequency of variants in AEBP1 among the gastroschisis case group compared to a Caucasian control group.
Most ACLP knockout mice die perinatally due to abdominal issues.
Both cellular proliferation and survival were affected in AEBP1-silenced U87MG and U138MG cell lines and a significant percentage of these cells were directed towards apoptosis.
This review focuses on the recently reported regulatory functions that adipocyte enhancer-binding protein 1 (AEBP1) exerts on PPARgamma1 and LXRalpha (show NR1H3 ELISA Kits) transcriptional activity in the context of macrophage cholesterol homeostasis and inflammation.
Transgenic overexpression of AEBP1 during adipogenesis coupled with a high-fat diet results in massive obesity in female transgenic mice via adipocyte hyperplasia.
ACLP and its discoidin-like domain may be novel targets for anti-myofibroblast-based therapies for the treatment of pulmonary fibrosis.
Stromal adipocyte enhancer-binding protein (AEBP1) promotes mammary epithelial cell hyperplasia via proinflammatory and hedgehog (show SHH ELISA Kits) signaling
Data suggest that macrophage AEBP1 plays critical regulatory roles in atherogenesis, and it may serve as a potential therapeutic target for the prevention or treatment of atherosclerosis.
Results describe the pathophysiological features of gastroschisis in aortic carboxypeptidase-like protein knockout mice and to characterize the neuromuscular development of the eviscerated intestine.
MAPK (show MAPK1 ELISA Kits) regulates the transcriptional activity of AEBP1 by a novel dual mechanism, in which MAPK (show MAPK1 ELISA Kits) interaction enhances and subsequent phosphorylation decreases the DNA-binding ability of AEBP1
AEBP1 plays critical regulatory roles in macrophage cholesterol homeostasis, foam cell formation, and proinflammation.
NF-kappaB (show NFKB1 ELISA Kits) activity is modulated by means of protein-protein interaction involving AEBP1 and IkappaBalpha (show NFKBIA ELISA Kits).
AEBP1 negatively regulates adipose tissue PTEN levels and has a key functional role in modulation of in vivo adiposity.
Adipocyte enhancer-binding protein 1 (AEBP1) is up-regulated during monocyte differentiation.
The adipocyte enhancer binding protein 1 is a transcriptional repressor with carboxypeptidase (CP) activity. This protein binds to a regulatory sequence, adipocyte enhancer 1 (AE-1), located in the proximal promoter region of the adipose P2 (aP2) gene, which encodes the adipocyte fatty-acid binding protein. It is characterized as a member of the regulatory B-like CP family. This protein seems to be activated by a novel mechanism, whereby the direct binding of DNA enhances its protease activity. Adipocyte-enhancer binding protein 1 may play a role in differentiated vascular smooth muscle cells.
AE binding protein 1
, adipocyte enhancer-binding protein 1
, aortic carboxypeptidase-like protein
, AE-binding protein 1